Methotrexate: Participants in the intervention group will receive methotrexate along side prednisolone
Placebo: Participants in the control arm will receive placebo along side prednisolone
Prednisolone: Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
Study summary
Erythema Nodosum Leprosum (ENL) is a painful, debilitating complication of leprosy. Patients often require high doses of corticosteroids for prolonged periods. Thalidomide is expensive and not available in most countries. The use of corticosteroids for long periods is associated with adverse effects and mortality. It is a priority to identify alternative agents to treat ENL. Methotrexate (MTX) is a cheap, widely used medication which has been reported to be effective in ENL resistant to steroids and thalidomide.
Eligibility
Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:: ALL OF THE FOLLOWING SIX CRITERIA MUST BE MET IN ORDER FOR AN INDIVIDUAL TO BE ELIGIBLE (ONLY ONE OF 6A TO 6D NEED BE MET):
1. Individuals who diagnosed with leprosy complicated by ENL
2. Individuals with ENL aged 18-60 years old
3. Individuals with ENL deteriorating symptoms
4. Individuals with 10 or more tender, papular or nodular ENL skin lesions
5. Individuals with an EESS score of at least 9
6. Individuals with ENL on:
1. No current anti- ENL treatment
2. Prednisolone up to 30mg per day (if ACUTE) or Prednisolone 10-30mg (inclusive) per day (if RECURRENT/ CHRONIC) or equivalent alternative corticosteroid dose OR
3. Thalidomide or other non-steroidal anti-ENL medication OR
4. A combination of prednisolone (up to 30mg) and another non-steroidal anti-ENL medication (thalidomide, clofazimine, azathioprine, pentoxifylline, ciclosporin, minocycline)
Exclusion criteria:
1. Individuals who were first diagnosed with ENL more than 4 years prior to enrolment
2. Individuals less than 18 years old or older than 60 years
3. Individuals weighing less than 35kg
4. Individuals with 9 or fewer tender, popular or nodular ENL skin lesions
5. Individuals with an EESS score of 8 or less
6. Women of child bearing capacity who decline to use two forms of adequate contraception and men who decline to use two forms of adequate contraception
7. Pregnant or breastfeeding women
8. Individuals with recurrent or chronic ENL who deteriorate on a dose of prednisolone less than 10 mg or more than 30 mg
9. Individuals who have taken methotrexate by any route for the last 12 weeks
10. Individuals with a hypersensitivity to methotrexate or a recognised contraindication ( please see Methotrexate information sheet)
11. Individuals currently diagnosed with Type 1 reaction or Lucio's phenomenon
12. Individuals with the severe abnormalities in screening investigations
13. Positive serology for HIV, Hepatitis B or C
14. Evidence of tuberculosis or pulmonary fibrosis
15. A history of chronic liver disease or excessive alcohol or illicit substance consumption
16. Individuals with severe inter-current infections, uncontrolled diabetes, active peptic ulcer disease, untreated malignancy
17. Individuals unable to attend regularly for assessment or monitoring
Primary outcome measure(s)
Proportion of individuals free from Erythema Nodosum Leprosum (ENL) flares in 24 weeks — During the first 24 weeks Proportion of individuals who have not required additional prednisolone during the first 24 weeks. The aim is to evaluate if individuals in the methotrexate regimen will need less prednisolone than the control arm.
Proportion of individuals free from ENL flares in 48 weeks — During first 48 weeks Proportion of individuals who have not required additional prednisolone during the first 48 weeks. To evaluate if methotrexate will be more efficient to control ENL than only prednisolone
Trial sites (7)
Facility
City
Region
Status
TMLI Bangladesh/ DBLM hospital
Dhaka
Bangladesh
FIOCRUZ
Rio de Janeiro
Brazil
ALERT
Addis Ababa
Ethiopia
The Leprosy Mission Trust
Delhi
India
Bombay Leprosy Project
Mumbai
India
Soetomo Hospital
Surabaya
Indonesia
Anandaban Hospital
Kathmandu
Nepal
More London School of Hygiene and Tropical Medicine trials in India
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.